Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $97.1 million.

  • Ligand Pharmaceuticals' Cash from Financing Activities rose 643.73% to $409.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $440.3 million, marking a year-over-year increase of 436.48%. This contributed to the annual value of $97.1 million for FY2024, which is 262.04% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Cash from Financing Activities of $97.1 million as of FY2024, which was up 262.04% from -$59.9 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Cash from Financing Activities ranged from a high of $97.1 million in FY2024 and a low of -$310.5 million during FY2020.
  • In the last 3 years, Ligand Pharmaceuticals' Cash from Financing Activities had a median value of -$59.9 million in 2023 and averaged -$79.6 million.
  • In the last 5 years, Ligand Pharmaceuticals' Cash from Financing Activities plummeted by 100.34% in 2022 and then soared by 262.04% in 2024.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Cash from Financing Activities stood at -$310.5 million in 2020, then surged by 55.64% to -$137.8 million in 2021, then crashed by 100.34% to -$276.0 million in 2022, then soared by 78.28% to -$59.9 million in 2023, then skyrocketed by 262.04% to $97.1 million in 2024.